Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool
Condition(s) studied
Investigational drug(s) / intervention(s)
Pediatric sepsis screening tool (either algorithmic or manual): All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.
Study summary
The overall objective of this proposed research is the derivation of a biomarker-enhanced artificial intelligence (AI)-based pediatric sepsis screening tool (PSCT) (software) that can be used in combination with the hospital's electronic health record (EHR) system to monitor and assess real-time emergency department (ED) electronic health record (EHR) data towards the enhancement of early pediatric sepsis recognition and the initiation of timely, aggressive personalized sepsis therapy known to improve patient outcomes.
It is hypothesized that the screening performance (e.g., positive predictive value) of the envisioned screening tool will be significantly enhanced by the inclusion of a biomarker panel test results (PERSEVERE) that have been shown to be effective in prediction of clinical deterioration in non-critically ill immunocompromised pediatric patients evaluated for infection. It is also hypothesized that enhanced phenotypes can be derived by clustering PERSEVERE biomarkers combined with routinely collected EHR data towards improved personalized medicine.
Eligibility
Primary outcome measure(s)
- Effective Expert System-based Pediatric Sepsis Screening Tool (PSCT) — Final 3 months of study period.
Over a usability test period, by emulation of the logic of experts in a screening tool that cam be continuously improved with experience, achieve a high level of ED workflow usability towards improved early recognition of IPSO sepsis, as perceived by practicing ED clinicians engaged in usability testing. - High performance Expert System-based Pediatric Sepsis Screening Tool (PSCT) — Using "early data" following presentation to ED, e.g., upon receipt of biomarker data within 1st 3 hours of presentation)
To derive a high performing (e.g., sensitivity/specificity \> 90%, PPV \> 40%) PSCT to identify patients in the ED meeting IPSO sepsis criteria using early encounter data (e.g. upon receipt of biomarker data within 1st 1-3 hours of presentation).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Children's National Hospital | Washington D.C. | District of Columbia |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05311046 on ClinicalTrials.gov ↗ ← All trials in the USA